DENVER, - Dr. Eli Lewis, a director of the Clinical Islet Laboratory with Ben-Gurion University of the Negev, Israel, has accepted a position on the Scientific Advisory Board of Omni Bio Pharmaceutical, Inc. ("OMNI") (OTCBB: AAFS)
In October 2008, Dr. Lewis co-published a study in the Proceedings of the National Academy of Sciences with OMNI Acting Chief Executive Officer Dr. Charles A. Dinarello and University of Colorado researcher Dr. Leland Shapiro titled "Alpha-1-Antitrypsin Monotherapy Induces Immune Tolerance During Islet Allograft Transplantation in Mice."
Dr. Lewis joins Dr. James Crapo and Dr. Michael Iseman, both physicians at National Jewish Health in Denver, and Dr. James Mier of Dana-Farber Harvard Cancer Center and Beth Israel Deaconess in Boston, on the Scientific Advisory Board of OMNI.
OMNI is the licensee of filed patents from the University of Colorado related to the treatment of graft rejection and transplantation using alpha-1 antitrypsin. The Company plans to conduct further research into the use of alpha-1 antitrypsin for the treatment of islet transplantation, and pursue commercialization of the Company's intellectual property upon the receipt of the proper regulatory approvals.
No comments:
Post a Comment